Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 168

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 168
---
 long as the market price of the Company’s common stock is above $1.25 per share and
(b) the Company is in full compliance with all agreements entered into with Coventry and

(c) and the Company has not issued any common shares at a per share price below $1.50,
Coventry will agree to a leak out provision and will not sell more than 10,000 shares of the Commitment shares without permission from the Issuer.

Quarter ended December 31, 2022

On October 25, 2022 the Company issued 6,667 Series A preferred shares as consideration for nonemployee services

On November 11, 2022 the Company issued 105126 Series A preferred shares in satisfaction of $761,500 of convertible indebtedness and $380,262 of accrued interest on convertible indebtedness.

On November 11, 2022 the Company issued 11,279 common shares in satisfaction of $25,639 of accrued interest on convertible indebtedness.

On December 5, 2022 the Company issued 1,112 Series A preferred shares as consideration for nonemployee services.

All the abovementioned securities were issued pursuant to Section 4(a) (2) of the securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The securities were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities. There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.

| 131 |

FORM OF SUBSCRIPTION AGREEMENT

<div align='center'>Subscription Agreement

REGEN BIOPHARMA, INC.

25,000,000 Shares of Common Stock, $0.0001 Par Value, Offered at $0.01per Share

Offering Amount: Up to $250,000

Minimum Purchase Amount: No Minimum

Sales will be made to Accredited Investors Only

Under Tier 2 of Regulation A+ of the Securities and Exchange Commission</div>

Subscriber Full Name:

________________________________________

Number of Shares Subscribed For:

________________________________________

INSTRUCTIONS

To purchase shares of the common stock (the “Shares”) of Regen Biopharma, Inc., a Nevada corporation (the “Company”) in the offering described above (the “Offering”), pursuant to the Regulation A+ Offering Circular originally filed with the SEC ON August 29, 2025 and supplemented on September 8,